Even though VEGF-expressing cells and serum VEGF/VEGFR levels have been associated with worse survival outcomes in some small studies performed in SCLC patients (61, 62), these molecules failed to be identified as predictive biomarkers for bevacizumab in the IFCT-0802 trial (15). This evidence concerns the gene VEGFA and small cell lung carcinoma.